Single-Use Endoscope Registration in Brazil: ANVISA Classification, Timeline & Cost

Single-use endoscopes are one of the fastest-moving product categories in medical devices — and Brazil is one of the markets where manufacturers most want them. This case study walks through how 21 endoscopy and visualization devices from 8 different manufacturers were registered with ANVISA under Pure Global's Brazil Registration Holder (BRH) model, what the records show about real timelines, and what the same path looks like for your product line.

Single-use endoscope registrations in Brazil: the snapshot

Across this group of 21 ANVISA registrations — single-use flexible endoscopes for urology, gynecology, and pulmonology, their video processors, and related visualization devices — the pattern is consistent: almost all of the devices classify as ANVISA Class II, filings were published typically within 3 to 6 weeks of submission, and not a single registration in the group required a deficiency (exigência) round. All 21 registrations are in force and were published in 2025 and 2026.

Those three facts — Class II classification, week-scale publication, zero deficiency rounds — are the whole story of why Brazil is a fast market for this category when the dossier is built correctly the first time.

Why single-use endoscopes are entering the Brazilian market

Reprocessing is the defining problem of flexible endoscopy: reusable scopes are complex to clean, and contamination incidents have pushed hospitals and regulators worldwide toward single-use alternatives for high-risk procedures. Brazil, with one of the largest hospital systems in the Americas, is following the same curve — and because single-use endoscopes remove the reprocessing burden entirely, they are an attractive proposition for Brazilian buyers.

For manufacturers, the commercial window rewards speed: the category is young, competition is arriving in waves, and being registered months earlier matters. That makes the regulatory path — and how predictably you can run it — a genuine competitive variable.

ANVISA classification for endoscopes: Class II and the notification pathway

Brazil regulates medical devices under RDC 751/2022, which classifies devices into four risk classes (I to IV) and splits the market-entry pathway accordingly: Class I and II devices follow the notification (notificação) route, while Class III and IV devices require full registration (registro) with substantive technical review.

Single-use endoscopes, their video processors, and most visualization accessories fall into Class II in this group's experience, with some simple accessories in Class I. That places the category on the notification route — the faster of ANVISA's two pathways. The work concentrates in getting the technical file right: device description and intended use aligned with ANVISA's classification rules, labeling and instructions for use in Brazilian Portuguese, and electrical-safety certification recognized in Brazil for powered devices such as processors.

One structural requirement shapes everything for foreign manufacturers: ANVISA requires a local registration holder. A manufacturer without a Brazilian subsidiary appoints a Brazil Registration Holder (BRH) — the local legal entity named on the registration that answers to ANVISA. Pure Global acts as BRH for the manufacturers in this group, which is also why these results are drawn from registrations we hold ourselves.

How to register an endoscope with ANVISA: the playbook from 21 filings

The registrations in this group followed a standardized sequence:

• Classification and family strategy first. Before any filing, each catalog was mapped against RDC 751 rules to confirm class and to group compatible models into families. Family grouping is the single biggest lever on cost and effort in Brazil — done well, an entire scope line with multiple sizes and configurations can enter under far fewer registrations than model-by-model filing would suggest.
• A dossier built for notification. The notification route is administrative, which means ANVISA publishes without a substantive review round — but the dossier still has to be complete and internally consistent, because deficiencies or inconsistencies surface later, at import or inspection. The group's zero-deficiency record reflects dossiers standardized across manufacturers rather than rebuilt from scratch each time.
• Portuguese labeling and IFU as a workstream, not an afterthought. Labeling in Brazilian Portuguese is mandatory and is the most common source of rework in this category. Templates shared across the group kept it predictable.
• Filing and publication through the BRH. As the registration holder, we file the notification, track it through ANVISA's queue, and the registration publishes in the Diário Oficial — at which point the device can legally be imported and sold.

ANVISA registration timeline for Class II devices: what 21 filings show

Across the group, filings were typically published within 3 to 6 weeks of submission — the fastest in under two weeks, and the median at roughly five weeks. None of the 21 registrations required a deficiency round.

Two honest caveats belong next to those numbers. First, the notification pathway is administrative: week-scale publication reflects ANVISA's process design plus dossier readiness, not special treatment — the value a partner adds is making sure the file is right the first time so the clock runs once. Second, higher-risk devices are a different story: Class III and IV devices go through substantive review measured in months, not weeks, so timelines from this Class II group do not transfer to, say, an implantable device.

Once published, Class II notifications in Brazil do not expire — there is no renewal cycle to manage for the registrations in this group, though the technical file must be kept current as products change.

ANVISA registration cost for endoscopes in Brazil

Brazil's government fee for a Class I/II notification is modest: BRL 1,406 per product (TFVS fee, current published rate). The larger budget lines are preparing a compliant dossier and maintaining a local holder. Pure Global's registration service for Brazil starts at US$2,000 per year, covering the BRH role, filing, and registration maintenance — you can model government fees and our fee together for your exact catalog in our pricing calculator.

Registering your endoscopy line in Brazil: where to start

The pattern in this case study is repeatable because none of it depends on a special case: classify correctly, group families deliberately, build the dossier for first-pass completeness, localize labeling properly, and file through a holder who answers for the registration. That is as true for a two-model startup as it is for the manufacturer in this group whose entire visualization line entered Brazil in a coordinated wave.

Start with the Brazil market page for the full regulatory picture, or talk to our team about your specific catalog.

About this case study

This profile describes a representative pattern across 21 real ANVISA registrations held by Pure Global's Brazilian entity for 8 different manufacturers. To protect client confidentiality, details are generalized and figures are shown as ranges or medians covering the underlying records; no individual client or product is identified. The underlying registrations are public records in ANVISA's regularized-device database. Source: ANVISA public registry and ANVISA open data, July 2026.